Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Norfolk Southern Corporation (NSC) Price & Performance

ACADIA Pharmaceuticals Inc.Trade
Norfolk Southern CorporationTrade

Price performance (Past 24H)

Key statistics

ACADIA Pharmaceuticals Inc. vs Norfolk Southern Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.71 (market cap $5.07B), while Norfolk Southern Corporation trades at $334.36 (market cap $75.15B). The key difference: Norfolk Southern Corporation is far larger — about 14.8× ACADIA Pharmaceuticals Inc.'s market cap, and Norfolk Southern Corporation pays a 1.61% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.

ACADNSC
Market Cap
$5.07B$75.15B
Sector
HealthTechnology
52-Week High
$29.41$350.66
52-Week Low
$20.06$272.35
Enterprise Value
$4.19B$90.70B
Dividend Yield
1.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.

Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.

Norfolk Southern Corporation

Norfolk Southern (NSC) trades at $332.82, down 0.34% on the day, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $3.52 per share, beating estimates, driven by record revenue and volume growth. Valuation ratios like P/E of 28.55 and P/S of 5.99 indicate a premium, while profitability remains solid with a net income margin of 21.02% and ROE of 16.97%. Recent news highlights merger developments with Union Pacific and institutional interest.

Outlook is cautiously optimistic due to earnings momentum and industry tailwinds, but risks include high fuel costs, merger execution uncertainties, and premium valuation. Analysts give a mixed consensus with 43.75% buy ratings and a $369.67 price target, suggesting modest upside potential from current levels amid competitive and operational headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Read more on ACAD

About Norfolk Southern Corporation

Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.

Read more on NSC